RxDoctor Payments Data

Linda Barkodar, MD

Internal Medicine · South Gate, CANPI 1124288147

Payments from drug & device makers

$1,854in general payments, 2019–2025

Across 24 payments — averaging $77.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$741
  • Regeneron Healthcare Solutions, Inc.$264
  • GSK$229
  • E.r. Squibb & Sons, L.L.C.$125
  • Amgen$122
  • AbbVie$107
  • plus $267 from 10 others

What the payments were for

  • Food & beverage$1,854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,854 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$8,232
Medicare patients
33
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$26,362
EliquisApixaban12$18,530
OzempicSemaglutide13$11,776
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$5,797
Atorvastatin Calcium94$860
Albuterol Sulfate HfaAlbuterol Sulfate18$716
Nifedipine ErNifedipine13$427
Benazepril Hcl30$398
Metoprolol Succinate17$342
Metformin Hcl45$338
Losartan Potassium29$324
Amlodipine Besylate51$286
Lisinopril47$260
Levothyroxine Sodium23$225
Omeprazole29$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$11,77613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →